Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene…
The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --…
25% Y-O-Y Revenue Growth in Q3 2023 Compared to Q3 2022 and 51% Increase in Gross Profit. ●In Q3 2023,…
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues…
Award builds on company’s 23-year state partnership to accelerate better health outcomes for Medicaid membersMCLEAN, Va., Nov. 14, 2023 (GLOBE…
Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts…
Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023…
ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA…
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern TimeYAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE)…
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate…